Nektar Therapeutics (NKTR) Misses Q2 EPS by 258c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $72.74 --0%
Revenue Growth %: -11.4%
Financial Fact:
Cost of goods sold: 7.03M
Today's EPS Names:
VIVO, PMCB, PLCE, More
Revenue Growth %: -11.4%
Financial Fact:
Cost of goods sold: 7.03M
Today's EPS Names:
VIVO, PMCB, PLCE, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($2.78), $2.58 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $11.17 million versus the consensus estimate of $9.74 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ciena beats estimates on strong AI-driven demand, shares rise
- BRP Inc. (DOO) Reports Q2 Loss of Cd$0.18
- Brady Corp. (BRC) Tops Q4 EPS by 1c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
